In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Procept BioRobotics completes $118mm late-stage round

Executive Summary

In what appears to be a Series E round, urology-focused Procept BioRobotics Corp. (minimally invasive water ablation therapy) raised $118mm in a financing led by new backer Viking Global Investors LP, which was joined by other new investor Perceptive Advisors and returning participants, including CPMG. The company will use the proceeds to fund worldwide commercialization of its Aquablation technology for benign prostatic hyperplasia (BPH). The company's robot-controlled AquaBeam waterjet-based prostate resection system, which incorporates the Aquablation platform, was cleared by the FDA via the de novo pathway in December 2017 (with an expected US launch in May 2018). The AquaBeam is already sold in Canada, Australia, New Zealand, and certain limited European markets.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register